One Milligram or Five: The Clinical Case for Reconsidering Your Finasteride Dose

For the vast majority of American men prescribed finasteride for androgenetic alopecia, the conversation ends at 1mg. The pill is small, the dose sounds reasonable, and the prescription gets filled without much deliberation. Yet behind that seemingly settled number lies a surprisingly contested body of clinical evidence — one that raises legitimate questions about whether 1mg is always the right choice, and whether the 5mg formulation deserves more serious consideration in the hair loss context.

Understanding the distinction requires a brief detour into pharmacology, followed by an honest assessment of what the research does and does not confirm.

Where the Two Doses Come From

Finasteride was not originally developed for hair loss. The 5mg formulation — sold under the brand name Proscar — was approved by the FDA in 1992 to treat benign prostatic hyperplasia (BPH), a condition in which the prostate gland enlarges and causes urinary symptoms. The drug works by inhibiting 5-alpha reductase, the enzyme responsible for converting testosterone into dihydrotestosterone (DHT). Since DHT is a primary driver of both prostate growth and follicular miniaturization in men genetically predisposed to hair loss, researchers recognized the drug's dual potential early on.

Propecia, the 1mg formulation specifically approved for male pattern baldness, received FDA clearance in 1997. The lower dose was selected based on clinical trials demonstrating that 1mg was sufficient to reduce scalp DHT by approximately 60 to 70 percent — a threshold researchers determined was adequate for meaningful hair preservation in most men.

The 5mg dose, by contrast, suppresses serum DHT by roughly 70 to 75 percent, a difference that sounds modest on paper but may carry clinical significance depending on the individual.

What the Research Actually Shows About Efficacy

The honest answer is that direct, head-to-head comparisons between 1mg and 5mg for androgenetic alopecia are limited. Most of the landmark hair loss trials — including the pivotal studies that supported Propecia's approval — used the 1mg dose exclusively. The 5mg data in the hair loss context is largely derived from studies originally designed around BPH populations, along with a smaller body of research specifically examining off-label use.

A frequently cited study published in the Journal of the American Academy of Dermatology found that 5mg finasteride produced comparable results to 1mg in terms of hair count and patient satisfaction, with no statistically significant superiority in efficacy. However, some dermatologists and hair restoration specialists argue that this interpretation undersells the real-world variability among patients — particularly those who show suboptimal responses at 1mg over time.

Anecdotal clinical experience and smaller observational studies suggest that a subset of men who plateau or regress on 1mg may experience renewed stabilization or modest regrowth when doses are increased. This has led some practitioners to view 5mg as a second-line option for non-responders rather than a first-line alternative.

The Cost-Benefit Calculation That Changes Everything

One of the most pragmatic arguments for 5mg finasteride is financial, and it is particularly relevant in the US market where drug pricing varies considerably by formulation.

Proscar (5mg) tablets can be split into quarters, yielding an approximate 1.25mg dose at a fraction of the cost of branded Propecia. Generic finasteride has substantially narrowed this gap, but the pill-splitting approach remains a common recommendation among cost-conscious clinicians. For men without insurance coverage for hair loss treatments — which describes the majority of American patients, since most insurers classify androgenetic alopecia as a cosmetic condition — this distinction can translate to hundreds of dollars in annual savings.

The counterargument is precision. Pill splitting introduces dosing variability, and a quartered 5mg tablet does not reliably deliver exactly 1.25mg. Whether that variability matters clinically is debatable, but it is a legitimate consideration.

Why Dermatologists Disagree

The wide variation in dosing recommendations across US dermatology practices reflects several converging factors. First, the FDA-approved indication is specifically 1mg, meaning 5mg prescribing for hair loss is by definition off-label. Some physicians are institutionally cautious about off-label prescribing, particularly when a labeled alternative exists.

Second, the side effect profile — which includes sexual dysfunction, decreased libido, and, in rare cases, persistent post-finasteride symptoms — is dose-dependent to some degree. Prescribing 5mg to a patient seeking hair preservation, rather than prostate management, raises the question of whether the incremental DHT suppression justifies any marginal increase in adverse event risk.

Third, and perhaps most importantly, individual patient response to finasteride varies considerably based on genetics, age, the extent of hair loss, and the duration of treatment. A 28-year-old in the early stages of recession may respond robustly to 1mg, while a 45-year-old with more advanced thinning might require closer clinical monitoring regardless of dose.

Practical Guidance for Patients Navigating the Dosing Question

If you are currently on 1mg finasteride and have been for at least 12 to 18 months without satisfactory results, the dosing question is worth raising explicitly with your prescribing physician or dermatologist. The conversation should include a frank assessment of your current DHT suppression response (which can be estimated through serum DHT testing, though this is not always routine), your side effect history, and your overall treatment goals.

For men just beginning treatment, 1mg remains the evidence-backed starting point. It is FDA-approved for this indication, carries a well-characterized safety profile, and is effective for the majority of patients who use it consistently over time.

For men who have genuinely plateaued — not simply grown impatient — a supervised trial at a higher dose, with careful monitoring, represents a clinically defensible path. It is not a decision to make unilaterally or based on online forums, but it is a conversation your doctor should be willing to have.

The Bottom Line

The 1mg versus 5mg debate is not a binary choice between right and wrong. It is a nuanced clinical question that depends on individual response, risk tolerance, cost considerations, and the stage of hair loss being treated. What matters most is that the conversation happens at all — because for too many men, the dose they were prescribed on day one is the dose they will take indefinitely, without ever asking whether a different approach might serve them better.